Johnson & Johnson has unveiled new data from Phase 3 trials for icotrokinra (JNJ-2113), an investigational oral peptide ...
Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...
a Phase 2b study of icotrokinra (JNJ-2113), the first investigational targeted oral peptide that selectively blocks the IL-23 receptor, in adults with moderately to severely active ulcerative ...
Johnson & Johnson announced new icotrokinra, JNJ-2113, data from its comprehensive Phase 3 clinical program and the start of the first-ever ...
Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...
today announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis (PsO) seeking to demonstrate ...
Zacks.com on MSN6d
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis StudyThe phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.
Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 ...
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback